Upfront Transplant Prevails Again in Newly Diagnosed Myeloma
An immunomodulatory-free carfilzomib (Kyprolis)-based triplet regimen failed to prove non-inferior to autologous hematopoietic stem-cell transplantation (HSCT) for the upfront treatment of newly diagnosed multiple myeloma, a randomized trial from the U.K. found. The open-label phase II CARDAMON study included nearly 300 patients, with 57.7% achieving at least a very good partial response (VGPR) with the […]